Schering Clarinex Approval Comes In Time For Big Spring Push
Executive Summary
Schering-Plough has received approval for the Claritin successor Clarinex in time to permit a big market build-up for the spring allergy season
You may also be interested in...
Fair Remedy Or Illegal Penalty? FDA Disgorgement Authority Questioned
Congress should examine whether FDA has the authority to seek disgorgement of profits and restitution in enforcement actions, Hyman, Phelps & McNamara principal John Fleder said Sept. 22
Fair Remedy Or Illegal Penalty? FDA Disgorgement Authority Questioned
Congress should examine whether FDA has the authority to seek disgorgement of profits and restitution in enforcement actions, Hyman, Phelps & McNamara principal John Fleder said Sept. 22
Schering Clarinex Reditabs approved
Schering-Plough's Clarinex Reditabs 5 mg clears FDA June 26 for treatment of allergy symptoms and chronic idiopathic urticaria. Product launch is "pending FDA approval of a quality control test revision, the supplement for which has already been submitted, and the build-up of sufficient inventories," the company said. Reditabs have been "approvable" since December (1"The Pink Sheet" Dec. 24, 2001, p. 34)...